Jianhua Yu

39PUBLICATIONS
117CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jun 17, 2026
Induced pluripotent stem cell-derived natural killer cells: poised for the clinic as an off-the-shelf allogeneic cell therapy.

|Feb 04, 2026
Human type-1 innate lymphoid cells control leukemia stem cell differentiation and limit acute myeloid leukemia development.

Zhenlong Li, Rui Ma, Hejun Tang

|Jan 06, 2026
Optimizing In Vivo CAR T-cell Engineering for Cancer Immunotherapy.

Ruiheng Wang, Jianhua Yu, Michael A Caligiuri

|Aug 18, 2025
Loss of YTHDF2 enhances Th9 programming and CAR-Th9 cell antitumor efficacy.

Sai Xiao, Songqi Duan, Yaqun Hong

|Feb 01, 2025
miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escape.

Fang Chen, Dandan Zhao, Yongfang Xu

|Jan 24, 2025
NKp46 enhances type 1 innate lymphoid cell proliferation and function and anti-acute myeloid leukemia activity.

Rui Ma, Zhenlong Li, Hejun Tang

Pageof 7

Frequent Collaborators

20 joint publications

Michael Caligiuri

6 joint publications

Shoubao Ma

6 joint publications

Li-Shu Wang

5 joint publications

Yi-Wen Huang